This is probably attributable to the high inhibitory concentration of MMZ (half-maximal inhibitory concentration (IC 50 ) of 17 mM) required to inhibit G6PD activity 44 , in contrast to G6PDi-1 and BMN, whose IC 50 s are in the submillimolar range (0.0730 M)
Additionally, the lack of federal regulatory oversight around compounded peptide products which are not subject to the same strict manufacturing and purity standards as FDA-approved drugs allows for safety concerns, such as potential risks of sterility issues, inaccurate dosages, unknown side effects, and product contamination
The biodistribution of Cy5-labeled SP and Cy5-labeled SP@M was then tested by in vivo imaging measurement of fluorescence intensity using a Caliper IVIS Lumina III In Vivo Imaging System (Perkin Elmer, USA) at specific time points (0.5, 6, and 24 h post-injection) ( n = 3 in each group)
While both compounds support cellular health and immune function, they differ significantly in bioavailability, mechanism of action, and practical applications
Small tweaks to the molecular structures allow the medications to avoid breakdown and exert their effects for longer periods of time
The team measured the levels of oxidative stress, oxidant damage and glutathione in the patients blood samples and compared them with those from healthy individuals
